For stage III epithelial ovarian cancer the initial level of expression of CA125 does not correlate with survival in women who respond to treatment

International Journal of Gynecological Cancer

Volumn 6, Issue 5, 1996, Pages 380-384

  Latimer, J A ^a,b   Beng, C G ^a   Davy, M L J ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

CA125; ovarian neoplasms; prognosis; survival

Indexed keywords

CA 125 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

EID: 0029756632     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1996.06050380.x     Document Type: Article

References (8)

1. Stratton JA, Rettenmaier MA, Phillips HB, Herabutya S, DiSaia PJ. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies. Obstet Gynecol 1988; 71: 20-6.
2. Ishiwata I, Ishiwata C, Soma M, Nozawa S, Ishikawa H. Characterization of newly established human ovarian carcinoma cell line - special reference of the effects of cis-platinum on cellular proliferation and release of CA125. Gynecol Oncol 1987; 26: 340-54.
3. Miwa K, Dozono H, Iemura K et al. The prognosis of ovarian cancer depends on the CA125 value at the end of induction therapy. Nippon Sanka Fujinka Gakkai Zasshi 1991; 43: 557-61.
4. Redman CW, Blackledge GR, Kelly K, Powell J, Buxton EJ, Luesley DM. Early serum CA125 response and outcome in epithelial ovarian cancer. Eur J Cancer 1990; 26: 593-6.
5. Buller RE, Berman ML, Bloss JD, Manetta A, DiSaia PJ. Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol 1992; 47: 87-92.
6. Friedlander M, Leary J, Russell P. An evaluation of CA125, CA1 and peanut lectin immunoreactivity in epithelial ovarian neoplasms: correlation with histopathological features, prognostic variables and patient outcome. Pathology 1988; 20: 38-44.
7. Fukazawa I, Inaba N, Ota Y et al. Relation between serum levels of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) and their immunohistochemical identification in benign and malignant gynecological disease. Arch Gynecol Obstet 1988; 243: 41-50.
8. Adachi S, Noda T, Kiyozuka Y et al. The importance of CA125 immunohistochemical staining in patients with ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi 1994; 46: 896-902.